Related Experiment Video
Updated: Apr 9, 2026
Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
Published on: April 12, 2024
Outcome and Prognostic Indicators in Cats Undergoing Splenectomy for Splenic Mast Cell Tumors
Kelly A Kraus1, Craig A Clifford1, Garrett J Davis1
1From the Surgery Department, Red Bank Veterinary Hospital, Tinton Falls, NJ (K.A.K., G.D.); Hope Veterinary Specialists, Malvern, PA (C.C.); Department of Clinical Sciences, College of Veterinary Medicine, University of Minnesota, St. Paul, MN (K.M.K.); and the Department of Clinical Studies, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA (K.D.).
Abstract:
This was a multi-institutional retrospective study evaluating the outcome and clinical parameters associated with the postoperative prognosis of 36 cats with splenic mast cell tumors treated with splenectomy. Clinical parameters reviewed included signalment, clinical history, results of staging tests, surgical variables, administration of blood products, presence of metastasis, postoperative complications, administration of chemotherapy postoperatively, chemotherapy protocol, and response to chemotherapy. Overall median survival time was 390 days (range, 2-1737 days). Administration of a blood product (P < .0001), metastasis to a regional lymph node (P = .022), and evidence of either concurrent or historical neoplasia (P = .037) were negatively associated with survival. Response to chemotherapy (P = .0008) was associated with an improved median survival time. Larger-scale prospective studies evaluating different chemotherapy protocols are required to elucidate the discrepancy between lack of survival benefit with administration of chemotherapy and improvement in survival time with positive response to chemotherapy.
